Skip to main content
Oncopeptides logo

Oncopeptides — Investor Relations & Filings

Ticker · ONCO ISIN · SE0009414576 LEI · 549300J9WWQ5CBYQ1M77 ST Manufacturing
Open in API
Filings indexed 483 across all filing types
Latest filing 2017-12-09 Earnings Release
Country SE Sweden
Listing ST ONCO

About Oncopeptides

https://www.oncopeptides.com/en

Oncopeptides is a biotechnology company focused on the research, development, and commercialization of targeted therapies for difficult-to-treat cancers. The company concentrates on hematological diseases, with a primary focus on multiple myeloma. Its commercialized product is Pepaxti (melflufen), a peptide-drug conjugate for adult patients with relapsed or refractory multiple myeloma. Founded in 2000 based on research from leading cancer institutions, Oncopeptides leverages its proprietary technology platforms to advance a pipeline of innovative drug candidates. The company's research also includes the development of Natural Killer (NK) cell engagers to address unmet medical needs in oncology.

Recent filings

Filing Released Lang Actions
Oncopeptides presented interim data from the ongoing phase II study HORIZON with Ygalo® (melflufen) at the 59th Annual Meeting of ASH today
Earnings Release Classification · 1% confidence The document is a press release announcing that interim data from the HORIZON phase II study for Ygalo® was presented at the 59th Annual Meeting of ASH (American Society of Hematology). It includes CEO comments, details about the data presented, and an announcement for a subsequent conference call to discuss the findings. This structure—announcing clinical data presentation and scheduling a call to discuss it—is characteristic of an Earnings Release (ER) or a general press release related to operational/clinical updates. Since it is focused on presenting new clinical data and scheduling a call to discuss it, it aligns best with an Earnings Release (ER) which often covers key operational/clinical highlights, or potentially a Regulatory Filing (RNS) if it were a mandatory disclosure. Given the focus on presenting interim data and scheduling a follow-up call, ER is a strong fit, as it communicates key periodic performance/update highlights. It is not a full report (10-K, IR), a presentation (IP), or a transcript (CT). It is an announcement of results/updates. FY 2017
2017-12-09 English
Oncopeptides presenterade idag interimsdata från den pågående fas II-studien HORIZON med Ygalo® (melflufen) på ASHs 59:e årsmöte
Earnings Release Classification · 1% confidence The document is a press release from Oncopeptides AB, dated December 9, 2017, announcing that interim data from their Phase II HORIZON study for Ygalo® was presented at the American Society of Hematology (ASH) annual meeting. It details the clinical results (ORR, CBR), provides context on the drug and the disease (multiple myeloma), and announces a subsequent conference call for investors/analysts to discuss the data presented at the conference. This structure—announcing clinical data presented at a medical conference and scheduling a follow-up call—is characteristic of an Earnings Release (ER) or a general announcement related to financial/clinical updates, but since it is primarily focused on releasing key clinical trial results and commentary from management following a major conference presentation, it aligns best with an Earnings Release (ER) which often includes key operational/clinical highlights, or potentially an Investor Presentation (IP) if it were the slides themselves. However, given the format is a press release summarizing results and announcing a call to discuss them, and it is not a full quarterly report (IR) or a formal presentation deck (IP), 'ER' (Earnings Release, used here broadly for key periodic results announcements) is the closest fit among the options, although 'RPA' (Report Publication Announcement) could also be considered if the focus was purely on the presentation being available. Since it contains substantive data summaries and management commentary, ER is stronger than RPA. It is not a 10-K, AR, or IR. FY 2017
2017-12-09 Swedish
Interim / Quarterly Report 2017
Interim / Quarterly Report Classification · 1% confidence The document is a 'Delårsrapport' (Interim Report) for the period July-September 2017 for Oncopeptides AB. It contains comprehensive financial data, including income statements, cash flow, and balance sheet summaries, as well as detailed management commentary on clinical trials and business strategy. It is not a mere announcement or certification, but the full interim report itself. Q3 2017
2017-11-15 Swedish
Interim / Quarterly Report 2017
Interim / Quarterly Report Classification · 1% confidence The document is titled 'Interim Report July - September 2017' and contains comprehensive financial statements, including a financial overview of the group, loss for the period, earnings per share, and cash flow data. It also includes a CEO statement and detailed business analysis. It is clearly a quarterly financial report, not an announcement or a summary, and meets the criteria for an Interim/Quarterly Report (IR). Q3 2017
2017-11-15 English
Oncopeptides kommer att delta vid Jefferies Healthcare Conference i London den 16 november.
Regulatory Filings Classification · 1% confidence The document is a short announcement from Oncopeptides AB stating that the company will participate in the Jefferies Healthcare Conference on November 16, 2017. It provides context about the company's drug candidate Ygalo® and mentions upcoming data presentations at ASH. Since the document is short (2206 characters) and its primary function is to announce participation in an external industry event (a conference presentation/attendance), it fits best under the category for announcements related to investor engagement or general regulatory updates that don't fit specific financial reporting types. Given the options, this is an announcement about future investor interaction, which is often categorized as a general regulatory filing or an announcement of an investor event. Since there is no specific 'Investor Event Announcement' code, and it is not a formal report (10-K, IR, ER), the most appropriate general category for this type of corporate communication is Regulatory Filings (RNS), or potentially Investor Presentation (IP) if it were the presentation itself, but here it is just an announcement of attendance. Given the nature of announcing participation in a conference, RNS is the safest fallback for non-standard announcements.
2017-11-07 Swedish
Oncopeptides to attend the Jefferies Healthcare Conference in London on November 16th
Regulatory Filings Classification · 1% confidence The document is a short press release announcing that the company, Oncopeptides, will be attending the Jefferies Healthcare Conference on a specific date. It provides brief background information on the company and its lead product candidate, Ygalo®. This type of announcement, which informs investors about participation in industry events or conferences, does not fit neatly into the specific financial reporting categories (like 10-K, ER, IR) or corporate action categories (like DIV, SHA, CAP). Since it is a general update aimed at investors regarding company activities and visibility, and it doesn't fit the definitions for AGM-R, CT, DIRS, LTR, or others, the most appropriate fallback category is Regulatory Filings (RNS), as it is a general regulatory announcement/press release.
2017-11-07 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.